Lymphoma is Driven by G.I. Dysbiosis

G.I. dysbiosis is identified
as one of the roots of cancer.

70% of the immune system lies in our G.I. microbiome. Optimizing the microbiome is key for anyone with a cancer diagnosis.

Growth and development of lymphomas, otherwise known as Lymphomagenesis, can be impacted by the microbiome. Research has demonstrated that the eradication of specific microorganismsfrom the gut microbiome leads to improved outcomes. Increased dominance by specific microbes in the microbiome can also play a role.

In functional oncology, we want to know what bacteria live in the G.I. microbiome of our lymphoma patients.

Research has shown the microbiome of patients prior to chemotherapy and/or immunotherapy can be a predictor of treatment outcomes across many lymphoma types. Higher microbial diversity, meaning you have a high number of different species that are evenly spread across your gut microbiome, is more common in patients who achieve a response to treatment compared with those who do not.

For patients in active treatment for lymphoma, a study to develop a bloodstream infection risk index for patients with non-Hodgkin lymphoma, who were undergoing stem cell transplantation, was able to accurately predict a patient’s risk of developing infection posttransplant. The study reveals pretreatment gut microbiome could be an important predictor infection risk after treatment.

What bacteria live in your microbiome?

Using stool study kits backed by research on the microbiome allows us to study the bacteria in your G.I. microbiome and make recommendations for treatment.

Stool studies offered by Hyperion Functional Medicine are key in optimizing the immune system in patients with cancer.

Call Hyperion Functional Medicine
to find out more about functional testing.

216.333.7860

Or make an appointment on the scheduling tab on our website for a free inspiration encounter to discuss your concerns surrounding lymphoma and a lymphoma treatment plan.

Supporting research:
Upadhyay Banskota S, Skupa SA, El-Gamal D, D’Angelo CR. Defining the Role of the Gut Microbiome in the Pathogenesis and Treatment of Lymphoid Malignancies. Int J Mol Sci. 2023 Jan 24;24(3):2309. doi: 10.3390/ijms24032309. PMID: 36768631; PMCID: PMC9916782.

Wiertsema SP, van Bergenhenegouwen J, Garssen J, Knippels LMJ. The Interplay between the Gut Microbiome and the Immune System in the Context of Infectious Diseases throughout Life and the Role of Nutrition in Optimizing Treatment Strategies. Nutrients. 2021 Mar 9;13(3):886. doi: 10.3390/nu13030886. PMID: 33803407; PMCID: PMC8001875.

Shi Z, Zhang M. Emerging Roles for the Gut Microbiome in Lymphoid Neoplasms. Clin Med Insights Oncol. 2021 Jun 17; 15:11795549211024197. doi: 10.1177/11795549211024197. PMID: 34211309; PMCID: PMC8216388.